Philip J Mease Selected Research

Biomarkers (Surrogate Marker)

1/2024	Modulation of IL-23 Signaling With Guselkumab in Biologic-Naïve Patients Versus TNF Inhibitor-Inadequate Responders With Active Psoriatic Arthritis.
11/2023	Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual Meeting.
1/2022	Basic Science Session 1. Biomarkers for Psoriatic Arthritis Treatment Response and Joint Damage Progression: An Update on 2 Industry-GRAPPA Projects.
1/2022	Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting.
6/2021	Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting.
6/2018	GRAPPA 2017 Project Report.
1/2016	GRAPPA 2015 Research and Education Project Reports.
6/2014	GRAPPA 2013 Annual Meeting, rheumatology updates: psoriatic arthritis (PsA) biomarker project, arthritis mutilans, PsA-peripheral spondyloarthritis epidemiology project.
5/2014	Updating the OMERACT filter: implications for imaging and soluble biomarkers.
8/2013	Biomarkers: project update from the GRAPPA 2012 annual meeting.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philip J Mease Research Topics

Disease

198	Psoriatic Arthritis 03/2024 - 04/2002
84	Psoriasis (Pustulosis Palmaris et Plantaris) 05/2024 - 07/2004
51	Pain (Aches) 05/2024 - 04/2005
32	Rheumatoid Arthritis 01/2023 - 07/2004
28	Fatigue 01/2024 - 04/2005
25	Ankylosing Spondylitis 12/2023 - 03/2007
22	Arthritis (Polyarthritis) 03/2024 - 05/2002
22	Fibromyalgia (Fibrositis) 06/2014 - 04/2005
19	Infections 05/2024 - 05/2007
17	Necrosis 02/2024 - 01/2013
11	Chronic Disease (Chronic Diseases) 01/2023 - 11/2011
9	Inflammation (Inflammations) 04/2023 - 04/2002
8	Axial Spondyloarthritis 05/2024 - 06/2013
6	Skin Diseases (Skin Disease) 12/2022 - 05/2011
6	Disease Progression 01/2018 - 07/2004
5	Sacroiliitis 12/2023 - 01/2016
5	Neoplasms (Cancer) 09/2023 - 05/2006
5	Non-Radiographic Axial Spondyloarthritis 04/2023 - 06/2013
5	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2023 - 09/2004
5	Skin Manifestations 01/2021 - 10/2005
5	Nausea 08/2020 - 02/2009
4	COVID-19 05/2024 - 01/2022
4	Joint Diseases (Joint Disease) 10/2023 - 05/2003
4	Opportunistic Infections (Opportunistic Infection) 09/2023 - 05/2006
4	Respiratory Tract Infections (Respiratory Tract Infection) 01/2022 - 04/2006
4	Headache (Headaches) 01/2022 - 02/2009
4	Musculoskeletal Diseases (Musculoskeletal Disease) 01/2020 - 02/2012
3	Uveitis 03/2024 - 12/2021
3	Cardiovascular Diseases (Cardiovascular Disease) 09/2023 - 01/2018
3	Spondylitis 08/2023 - 08/2013
3	Herpes Zoster 01/2023 - 06/2021
3	Nasopharyngitis 01/2022 - 09/2015
3	Diarrhea 08/2020 - 09/2009
3	Autoimmune Diseases (Autoimmune Disease) 01/2020 - 07/2008
2	Melanoma (Melanoma, Malignant) 01/2023 - 11/2010
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2023 - 12/2021
2	Skin Neoplasms (Skin Cancer) 01/2023 - 11/2010
2	Mycoses (Diseases, Fungus) 01/2023 - 07/2009
2	Nail Diseases (Nail Disease) 05/2022 - 05/2007
2	Ulcerative Colitis 01/2021 - 01/2018
2	Crohn Disease (Crohn's Disease) 01/2020 - 01/2018
2	Candidiasis (Moniliasis) 01/2020 - 01/2018
2	Back Pain (Backache) 01/2016 - 06/2013
2	Stroke (Strokes) 10/2015 - 02/2011
2	Myocardial Infarction 10/2015 - 02/2011
2	Knee Osteoarthritis 08/2015 - 05/2014

Drug/Important Bio-Agent (IBA)

34	secukinumabIBA 03/2024 - 03/2014
31	Antirheumatic Agents (DMARD)IBA 03/2024 - 05/2003
29	guselkumabIBA 03/2024 - 03/2015
25	Methotrexate (Mexate)FDA LinkGeneric 03/2024 - 05/2003
23	Adalimumab (Humira)FDA Link 04/2023 - 07/2005
21	Biomarkers (Surrogate Marker)IBA 01/2024 - 03/2007
19	ametantrone (HAQ)IBA 02/2024 - 01/2008
18	Interleukin-17 (Interleukin 17)IBA 03/2024 - 03/2014
16	Monoclonal AntibodiesIBA 11/2023 - 10/2005
16	C-Reactive ProteinIBA 10/2022 - 03/2007
15	Etanercept (Enbrel)FDA Link 01/2022 - 04/2002
14	Tumor Necrosis Factor InhibitorsIBA 03/2024 - 05/2010
14	tofacitinibIBA 01/2024 - 01/2019
13	apremilastIBA 09/2023 - 03/2014
13	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019 - 04/2002
12	ixekizumabIBA 01/2022 - 03/2014
10	Janus Kinase InhibitorsIBA 02/2024 - 01/2019
9	bimekizumabIBA 04/2024 - 01/2023
9	InterleukinsIBA 03/2024 - 03/2015
9	Interleukin-23 (Interleukin 23)IBA 01/2024 - 03/2015
9	Milnacipran (Ixel)FDA Link 06/2014 - 10/2005
9	Duloxetine Hydrochloride (Cymbalta)FDA Link 06/2011 - 06/2008
7	Prostaglandins AIBA 02/2024 - 05/2011
7	Rituximab (Mabthera)FDA Link 05/2013 - 01/2008
6	Certolizumab Pegol FDA Link 04/2023 - 02/2011
6	CytokinesIBA 01/2020 - 04/2002
5	upadacitinibIBA 01/2023 - 01/2021
5	brodalumabIBA 01/2021 - 03/2014
5	Pregabalin (Lyrica)FDA Link 06/2013 - 04/2005
4	Immunoglobulin A (IgA)IBA 01/2024 - 01/2022
4	Rheumatoid FactorIBA 12/2021 - 05/2007
4	Abatacept (Orencia)FDA Link 07/2020 - 09/2017
4	Phosphodiesterase 4 InhibitorsIBA 01/2018 - 06/2014
4	Serotonin (5 Hydroxytryptamine)IBA 08/2011 - 12/2009
4	Norepinephrine (Noradrenaline)FDA LinkGeneric 03/2011 - 02/2009
3	Immunomodulating AgentsIBA 05/2024 - 11/2010
3	deucravacitinibIBA 03/2024 - 01/2022
3	TYK2 Kinase (Tyrosine Kinase 2)IBA 03/2024 - 01/2022
3	Interleukin-23 Subunit p19IBA 03/2024 - 01/2020
3	Analgesics (Analgesic Drugs)IBA 11/2020 - 12/2009
3	Infliximab (Remicade)FDA Link 03/2014 - 05/2003
3	Dehydroepiandrosterone (DHEA)IBA 08/2008 - 09/2004
2	HLA-B27 Antigen (HLA B27 Antigen)IBA 05/2022 - 01/2016
2	COVID-19 VaccinesIBA 06/2021 - 03/2021
2	Interleukin-17 ReceptorsIBA 01/2021 - 06/2014
2	tildrakizumabIBA 01/2021 - 03/2015
2	Acute-Phase Proteins (Acute-Phase Protein)IBA 01/2020 - 05/2007
2	amsonic acid (DAS)IBA 11/2018 - 11/2017
2	Proteins (Proteins, Gene)FDA Link 11/2015 - 01/2013

Therapy/Procedure

62	Therapeutics 05/2024 - 05/2002
8	Drug Therapy (Chemotherapy) 06/2021 - 03/2007
5	Biological Therapy 04/2020 - 11/2005
2	Aftercare (After-Treatment) 03/2024 - 01/2014
2	Immunomodulation 01/2022 - 11/2010